9月27日盘后,百利天恒(SH688506,股价163.10元,市值654.03亿元)公告,合作方百时美施贵宝(以下简称BMS)获得美国食品药品监督管理局(以下简称FDA)通知,BL-B01D1联合用药项目用于治疗晚期实体瘤的1/2a期临床试验申请已获得FDA许可。 自2023年12月百利天恒与BMS就BL-B01D1达成合作后,BMS积极推动BL-B01D1的全球临床开发,并逐步推进至国际...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.